Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 402

1.

Thromboembolism in the Absence of Atrial Fibrillation.

Smietana J, Plitt A, Halperin JL.

Am J Cardiol. 2019 Jul 15;124(2):303-311. doi: 10.1016/j.amjcard.2019.04.027. Epub 2019 Apr 25. Review.

PMID:
31060729
2.

Improved scoring system for the electrocardiographic diagnosis of left ventricular hypertrophy.

Braunstein ED, Croft LB, Halperin JL, Liao SL.

World J Cardiol. 2019 Mar 26;11(3):94-102. doi: 10.4330/wjc.v11.i3.94.

3.

Deep learning for cardiovascular medicine: a practical primer.

Krittanawong C, Johnson KW, Rosenson RS, Wang Z, Aydar M, Baber U, Min JK, Tang WHW, Halperin JL, Narayan SM.

Eur Heart J. 2019 Feb 27. pii: ehz056. doi: 10.1093/eurheartj/ehz056. [Epub ahead of print]

PMID:
30815669
4.

Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention.

Kerneis M, Yee MK, Mehran R, Nafee T, Bode C, Halperin JL, Peterson ED, Verheugt FWA, Wildgoose P, van Eickels M, Lip GYH, Cohen M, Fox KAA, Gibson CM.

Circ Cardiovasc Interv. 2019 Feb;12(2):e007124. doi: 10.1161/CIRCINTERVENTIONS.118.007124.

PMID:
30704287
5.

ACC/AHA/SCAI/SIR/SVM 2018 Appropriate Use Criteria for Peripheral Artery Intervention: A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Heart Association, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, and Society for Vascular Medicine.

Bailey SR, Beckman JA, Dao TD, Misra S, Sobieszczyk PS, White CJ, Wann LS, Bailey SR, Dao T, Aronow HD, Fazel R, Gornik HL, Gray BH, Halperin JL, Hirsch AT, Jaff MR, Krishnamurthy V, Parikh SA, Reed AB, Shamoun F, Shugart RE, Yucel EK.

J Am Coll Cardiol. 2019 Jan 22;73(2):214-237. doi: 10.1016/j.jacc.2018.10.002. Epub 2018 Dec 17. No abstract available.

PMID:
30573393
6.

No conflict of interest in data monitoring.

Halperin JL.

Science. 2018 Dec 7;362(6419):1123. doi: 10.1126/science.aau9738. No abstract available.

PMID:
30523103
7.

Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial.

Quinn GR, Hellkamp AS, Hankey GJ, Becker RC, Berkowitz SD, Breithardt G, Fava M, Fox KAA, Halperin JL, Mahaffey KW, Nessel CC, Patel MR, Piccini JP, Singer DE.

J Am Heart Assoc. 2018 Aug 7;7(15):e008755. doi: 10.1161/JAHA.118.008755.

8.

Three-dimensional echocardiography demonstrates a skewered left ventricular thrombus in a patient with a heart transplant.

Gannon MP, Saba SG, Hirsh BJ, Halperin JL, Garcia MJ, Pinney SP, Goldman ME.

Echocardiography. 2018 Dec;35(12):2117-2120. doi: 10.1111/echo.14158. Epub 2018 Oct 18.

PMID:
30338540
9.

US Preventive Services Task Force recommendation statement regarding screening for peripheral artery disease with the ankle-brachial index: déjà vu all over again.

Olin JW, Halperin JL.

Lancet. 2018 Sep 29;392(10153):1160-1162. doi: 10.1016/S0140-6736(18)31650-7. No abstract available.

PMID:
30303084
10.

Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF.

Chen ST, Hellkamp AS, Becker RC, Berkowitz SD, Breithardt G, Fox KAA, Hacke W, Halperin JL, Hankey GJ, Mahaffey KW, Nessel CC, Piccini JP, Singer DE, Patel MR, Melloni C.

Eur Heart J Qual Care Clin Outcomes. 2019 Apr 1;5(2):145-152. doi: 10.1093/ehjqcco/qcy040.

PMID:
30219887
11.

Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness.

Spyropoulos AC, Ageno W, Albers GW, Elliott CG, Halperin JL, Hiatt WR, Maynard GA, Steg PG, Weitz JI, Suh E, Spiro TE, Barnathan ES, Raskob GE; MARINER Investigators.

N Engl J Med. 2018 Sep 20;379(12):1118-1127. doi: 10.1056/NEJMoa1805090. Epub 2018 Aug 26.

12.

Safety and efficacy of non-vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial.

Chi G, Kerneis M, Kalayci A, Liu Y, Mehran R, Bode C, Halperin JL, Verheugt FWA, Wildgoose P, van Eickels M, Lip GYH, Cohen M, Peterson ED, Fox KAA, Gibson CM.

Am Heart J. 2018 Sep;203:17-24. doi: 10.1016/j.ahj.2018.06.003. Epub 2018 Jun 13.

PMID:
30015064
13.

Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention.

Chi G, Yee MK, Kalayci A, Kerneis M, AlKhalfan F, Mehran R, Bode C, Halperin JL, Verheugt FWA, Wildgoose P, van Eickels M, Lip GYH, Cohen M, Peterson ED, Fox KAA, Gibson CM.

J Thromb Thrombolysis. 2018 Oct;46(3):346-350. doi: 10.1007/s11239-018-1703-5.

PMID:
29943350
14.

Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AF.

Chen ST, Hellkamp AS, Becker RC, Berkowitz SD, Breithardt G, Fox KAA, Hacke W, Halperin JL, Hankey GJ, Mahaffey KW, Nessel CC, Piccini JP, Singer DE, Patel MR.

Am Heart J. 2018 Jun;200:102-109. doi: 10.1016/j.ahj.2018.02.013. Epub 2018 Feb 27.

PMID:
29898836
15.

Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial.

Ezekowitz MD, Pollack CV Jr, Halperin JL, England RD, VanPelt Nguyen S, Spahr J, Sudworth M, Cater NB, Breazna A, Oldgren J, Kirchhof P.

Eur Heart J. 2018 Aug 21;39(32):2959-2971. doi: 10.1093/eurheartj/ehy148.

16.

Gender Differences in Antithrombotic Treatment for Newly Diagnosed Atrial Fibrillation: The GLORIA-AF Registry Program.

Mazurek M, Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Zint K, França LR, Lu S, Lip GYH; GLORIA-AF Investigators.

Am J Med. 2018 Aug;131(8):945-955.e3. doi: 10.1016/j.amjmed.2018.03.024. Epub 2018 Apr 11.

PMID:
29654720
17.

Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial fibrillation: Global Registry on Long-Term Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) registry.

Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma CS, Zint K, Elsaesser A, Lu S, Bartels DB, Lip GYH; GLORIA-AF Investigators.

Am Heart J. 2018 Apr;198:55-63. doi: 10.1016/j.ahj.2017.08.018. Epub 2017 Aug 31.

PMID:
29653649
18.

Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial.

Kerneis M, Gibson CM, Chi G, Mehran R, AlKhalfan F, Talib U, Pahlavani S, Mir M, Bode C, Halperin JL, Nafee T, Peterson ED, Verheugt FWA, Wildgoose P, van Eickels M, Lip GYH, Fox KAA, Cohen M.

JACC Cardiovasc Interv. 2018 Apr 9;11(7):626-634. doi: 10.1016/j.jcin.2017.11.009. Epub 2018 Mar 14.

19.

Stroke-prevention strategies in North American patients with atrial fibrillation: The GLORIA-AF registry program.

McIntyre WF, Conen D, Olshansky B, Halperin JL, Hayek E, Huisman MV, Lip GYH, Lu S, Healey JS.

Clin Cardiol. 2018 Jun;41(6):744-751. doi: 10.1002/clc.22936. Epub 2018 May 10.

20.

Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AF.

Barnett AS, Cyr DD, Goodman SG, Levitan BS, Yuan Z, Hankey GJ, Singer DE, Becker RC, Breithardt G, Berkowitz SD, Halperin JL, Hacke W, Mahaffey KW, Nessel CC, Fox KAA, Patel MR, Piccini JP.

Int J Cardiol. 2018 Apr 15;257:78-83. doi: 10.1016/j.ijcard.2017.06.110.

PMID:
29506743

Supplemental Content

Loading ...
Support Center